Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imaging of Solid Tumors Using 18F-TRX
NCT06942104Phase 1Recruiting
- Sponsor
- Rahul Aggarwal
- Start
- Jul 2025
- Primary completion
- Sep 2027
- Modality
- Radiopharmaceutical
- Countries
- 1
01
Overview
Phase 1, open-label trial of 18F-TRX in solid tumor, glioma, clear cell renal cell carcinoma (ccRCC) and 1 more (2 cohorts), sponsored by Rahul Aggarwal. Primary endpoint: Proportion of participants with treatment-emergent adverse events up to 7 days. Started Jul 2025; status: recruiting.
02
Drugs
18F-TRX
03
Conditions
solid tumorgliomaclear cell renal cell carcinoma (ccRCC)castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT06942104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06942104.